Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 earnings call Highlights: strategic focus and …

• Revenue: $ 29.4 million for the first quarter of 2025, compared to 38 million US dollars in the first quarter of 2024.

• Research and development costs: 34.9 million USD for the first quarter of 2025, compared to USD 53.6 million in the first quarter of 2024.

• General and administrative costs: $ 11.3 million for the first quarter of 2025, compared to $ 14.9 million in the first quarter of 2024.

• Net lust: Approx. $ 14.1 million or $ 0.52 per diluted share for quarter 2025.

• Cash and cash equivalent: $ 273.8 million on March 31, 2025, compared to $ 293 million on December 31, 2024.

• Cash Runway: Extended to Q1 2028.

Appearance date: May 12, 2025

You can find the complete copy of the earnings call in the complete earnings call.

• Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) promotes his mRNA therapy pipeline with significant advances in clinical studies on cystic fibrosis (ARCT-032) and ornithine trans-carbamylase deficiency (ARCT-810).

• The company received the EU approval for the self-amplificating mRNA Covid-19 vaccine, costatic, and an initial milestone payment of its global vaccine partner CSL.

• Arcturus Therapeutics Holdings Inc (Nasdaq: Arct) has extended his cash landing railway to the first quarter of 2028, so that it can concentrate on its critical CF and OTC programs.

• The company received the US FDA almost track name for its SA-MRNA vaccine candidate for the Pandemic influenza A (H5N1), ARCT-2304.

• Arcturus Therapeutics Holdings Inc (Nasdaq: Arct) is in a strong financial position with cash and cash equivalents of $ 273.8 million on March 31, 2025.

• The income for the first quarter of 2025 decreased from $ 38 million in the same period from 2024 to $ 29.4 million, especially due to the lower milestone income for development.

• Research and development costs went back from USD 53.6 million in the comparable period of the previous year to $ 34.9 million, which is due to lower manufacturing costs, but also indicates reduced activities in some areas.

• The company reported a net loss of around $ 14.1 million in the first quarter of 2025, which resulted in the ongoing financial challenges.

• Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has made the decision to concentrate his research and development expenses exclusively on his CF and OTC programs and possibly limit diversification.

• By 2028, there are no expected milestone payments from Great Britain or US submissions for custody, which may affect short-term financial expectations.

Q: Can you provide further details about the changes to expand the cash landing railway and the potential incoming cash flows? A: Andrew Sassine, CFO, explained that the decision to concentrate on the two most critical programs CF and OTC included cost reductions, including the elimination of early development programs and consolidation institutions. This strategic focus, together with conservative cash burns, has contributed to expanding the Cash Landenbahn to 2028.